regulatory
confidence high
sentiment positive
materiality 0.85
Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year
VERTEX PHARMACEUTICALS INC / MA
- FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.
- Annual wholesale acquisition cost in the U.S. is $370,269 ($28,404 per 28-day pack).
- Approval expands Vertex's cystic fibrosis treatment portfolio.